Summary of Study ST002944

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001831. The data can be accessed directly via it's Project DOI: 10.21228/M81Q73 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002944
Study TitleLongitudinal polar fecal metabolomics of mice undergoing sensitization to beta-lactoglobulin
Study Type(un)targeted MS
Study SummaryThis study is part of a multi-part study, including a. longitudinal polar fecal metabolomics of mice undergoing sensitization to beta-lactoglobulin b. polar fecal metabolomics of a patient cohort c. fecal lipidomics of a patient cohort d. polar urinary metabolomics of a patient cohort e. polar metabolomics of in vitro digestions This specific part is part a. longitudinal polar fecal metabolomics of mice undergoing sensitization to beta-lactoglobulin
Institute
Ghent University
DepartmentDepartment of Translational Physiology, Infectiology and Public Health
LaboratoryLaboratory for Integrative Metabolomics
Last NameDe Paepe
First NameEllen
AddressSalisburylaan 133, 9820 Merelbeke, Belgium
EmailEllen.DePaepe@UGent.be
Phone0032479081098
Submit Date2023-07-06
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2023-11-01
Release Version1
Ellen De Paepe Ellen De Paepe
https://dx.doi.org/10.21228/M81Q73
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001831
Project DOI:doi: 10.21228/M81Q73
Project Title:Integrated gut metabolome and microbiome fingerprinting reveals that dysbiosis precedes allergic inflammation in IgE-mediated pediatric cow’s milk allergy
Project Type:(un)targeted MS
Project Summary:Background: IgE-mediated cow’s milk allergy (IgE-CMA) is one of the first allergies to arise in early childhood and may result from exposure to various milk allergens, of which β-lactoglobulin (BLG) and casein are the most important. Understanding the underlying mechanisms behind IgE-CMA is imperative for the discovery of novel biomarkers and the design of innovative treatment and prevention strategies. Methods: We report a longitudinal in vivo murine model, in which 2 mice strains (BALB/c and C57Bl/6) were sensitized to BLG using either cholera toxin or an oil emulsion (n=6 per group). After sensitization, mice were challenged orally, their clinical signs monitored, antibody (IgE and IgG1) and cytokine levels (IL-4 and IFN-γ) measured, and fecal samples subjected to metabolomics. The results of the murine models were further supported by fecal microbiome-metabolome data from our population of IgE-CMA (n=24) and healthy (n=23) children (Trial: NCT04249973), on which polar metabolomics, lipidomics and 16S rRNA metasequencing were performed. In vitro gastrointestinal digestions and multi-omics corroborated the microbial origin of proposed metabolic changes. Results: During sensitization, we observed multiple microbially derived metabolic alterations, most importantly bile acid, energy and tryptophan metabolites, that preceded allergic inflammation. The latter was reflected in a disturbed sphingolipid metabolism. We confirmed microbial dysbiosis, and its causal effect on metabolic alterations in our patient cohort, which was accompanied by metabolic signatures of low-grade inflammation. Conclusion: Our results indicate that gut dysbiosis precedes allergic inflammation and nurtures a chronic low-grade inflammation in children on elimination diets, opening important new opportunities for future prevention and treatment strategies.
Institute:Ghent University
Department:Translational Physiology, Infectiology and Public Health
Laboratory:Laboratory for Integrative Metabolomics
Last Name:De Paepe
First Name:Ellen
Address:Salisburylaan 133, Merelbeke, Oost-Vlaanderen, 9820, Belgium
Email:Ellen.DePaepe@UGent.be
Phone:0032479081098
Funding Source:Fonds Wetenschappelijk Onderzoek

Subject:

Subject ID:SU003057
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090
Genotype Strain:BALB/c and C57Bl/6
Age Or Age Range:3-10 weeks
Gender:Female
Animal Animal Supplier:Charles River
Animal Housing:SPF
Animal Feed:Sniff
Animal Water:Ad libitum

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Strain
SA320431S_21_0066_35B6 | treatment:1A | week:Wk 1
SA320432S_21_0066_191B6 | treatment:1A | week:Wk 4
SA320433S_21_0066_179B6 | treatment:1B | week:Wk 4
SA320434S_21_0066_129B6 | treatment:1C | week:Wk 1
SA320435S_21_0066_205B6 | treatment:1C | week:Wk 4
SA320436S_21_0066_75B6 | treatment:1D | week:Wk 4
SA320437S_21_0066_125B6 | treatment:1E | week:Wk 1
SA320438S_21_0066_34B6 | treatment:1E | week:Wk 4
SA320439S_21_0066_31B6 | treatment:1F | week:Wk 1
SA320440S_21_0066_124B6 | treatment:1F | week:Wk 4
SA320441S_21_0066_16B6 | treatment:1W | week:Wk 1
SA320442S_21_0066_190B6 | treatment:1X | week:Wk 1
SA320443S_21_0066_273B6 | treatment:1X | week:Wk 7
SA320444S_21_0066_245B6 | treatment:1Y | week:Wk 7
SA320445S_21_0066_308B6 | treatment:1Z | week:Wk 1
SA320446S_21_0066_236B6 | treatment:1Z | week:Wk 7
SA320447S_21_0066_267B6 | treatment:2A | week:Wk 1
SA320448S_21_0066_93B6 | treatment:2A | week:Wk 4
SA320449S_21_0066_195B6 | treatment:2B | week:Wk 4
SA320450S_21_0066_211B6 | treatment:2C | week:Wk 1
SA320451S_21_0066_193B6 | treatment:2C | week:Wk 4
SA320452S_21_0066_8B6 | treatment:2D | week:Wk 4
SA320453S_21_0066_86B6 | treatment:2E | week:Wk 1
SA320454S_21_0066_158B6 | treatment:2E | week:Wk 4
SA320455S_21_0066_23B6 | treatment:2F | week:Wk 4
SA320456S_21_0066_126B6 | treatment:2W | week:Wk 1
SA320457S_21_0066_263B6 | treatment:2X | week:Wk 1
SA320458S_21_0066_244B6 | treatment:2X | week:Wk 7
SA320459S_21_0066_207B6 | treatment:2Y | week:Wk 7
SA320460S_21_0066_260B6 | treatment:2Z | week:Wk 1
SA320461S_21_0066_254B6 | treatment:3A | week:Wk 1
SA320462S_21_0066_132B6 | treatment:3A | week:Wk 4
SA320463S_21_0066_73B6 | treatment:3B | week:Wk 4
SA320464S_21_0066_60B6 | treatment:3C | week:Wk 1
SA320465S_21_0066_222B6 | treatment:3C | week:Wk 4
SA320466S_21_0066_21B6 | treatment:3D | week:Wk 4
SA320467S_21_0066_264B6 | treatment:3E | week:Wk 4
SA320468S_21_0066_282B6 | treatment:3F | week:Wk 4
SA320469S_21_0066_116B6 | treatment:3W | week:Wk 1
SA320470S_21_0066_294B6 | treatment:3W | week:Wk 7
SA320471S_21_0066_271B6 | treatment:3X | week:Wk 1
SA320472S_21_0066_262B6 | treatment:3X | week:Wk 7
SA320473S_21_0066_118B6 | treatment:3Z | week:Wk 1
SA320474S_21_0066_41B6 | treatment:3Z | week:Wk 7
SA320475S_21_0066_151B6 | treatment:4A | week:Wk 4
SA320476S_21_0066_56B6 | treatment:4B | week:Wk 1
SA320477S_21_0066_71B6 | treatment:4B | week:Wk 4
SA320478S_21_0066_202B6 | treatment:4C | week:Wk 1
SA320479S_21_0066_103B6 | treatment:4C | week:Wk 4
SA320480S_21_0066_198B6 | treatment:4D | week:Wk 1
SA320481S_21_0066_172B6 | treatment:4D | week:Wk 4
SA320482S_21_0066_268B6 | treatment:4E | week:Wk 1
SA320483S_21_0066_47B6 | treatment:4E | week:Wk 4
SA320484S_21_0066_229B6 | treatment:4F | week:Wk 4
SA320485S_21_0066_5B6 | treatment:4W | week:Wk 1
SA320486S_21_0066_286B6 | treatment:4W | week:Wk 7
SA320487S_21_0066_261B6 | treatment:4X | week:Wk 1
SA320488S_21_0066_12B6 | treatment:4X | week:Wk 7
SA320489S_21_0066_168B6 | treatment:4Y | week:Wk 1
SA320490S_21_0066_13B6 | treatment:4Y | week:Wk 7
SA320491S_21_0066_288B6 | treatment:4Z | week:Wk 7
SA320492S_21_0066_252B6 | treatment:5A | week:Wk 1
SA320493S_21_0066_233B6 | treatment:5A | week:Wk 4
SA320494S_21_0066_62B6 | treatment:5B | week:Wk 1
SA320495S_21_0066_184B6 | treatment:5B | week:Wk 4
SA320496S_21_0066_102B6 | treatment:5C | week:Wk 1
SA320497S_21_0066_101B6 | treatment:5C | week:Wk 4
SA320498S_21_0066_55B6 | treatment:5D | week:Wk 1
SA320499S_21_0066_20B6 | treatment:5D | week:Wk 4
SA320500S_21_0066_58B6 | treatment:5E | week:Wk 1
SA320501S_21_0066_209B6 | treatment:5E | week:Wk 4
SA320502S_21_0066_50B6 | treatment:5F | week:Wk 1
SA320503S_21_0066_206B6 | treatment:5F | week:Wk 4
SA320504S_21_0066_274B6 | treatment:5W | week:Wk 1
SA320505S_21_0066_311B6 | treatment:5W | week:Wk 7
SA320506S_21_0066_36B6 | treatment:5X | week:Wk 1
SA320507S_21_0066_174B6 | treatment:5X | week:Wk 7
SA320508S_21_0066_37B6 | treatment:5Y | week:Wk 1
SA320509S_21_0066_306B6 | treatment:5Y | week:Wk 7
SA320510S_21_0066_287B6 | treatment:5Z | week:Wk 1
SA320511S_21_0066_139B6 | treatment:5Z | week:Wk 7
SA320512S_21_0066_61B6 | treatment:6A | week:Wk 1
SA320513S_21_0066_53B6 | treatment:6A | week:Wk 4
SA320514S_21_0066_80B6 | treatment:6B | week:Wk 4
SA320515S_21_0066_18B6 | treatment:6C | week:Wk 1
SA320516S_21_0066_266B6 | treatment:6C | week:Wk 4
SA320517S_21_0066_128B6 | treatment:6D | week:Wk 1
SA320518S_21_0066_28B6 | treatment:6D | week:Wk 4
SA320519S_21_0066_279B6 | treatment:6E | week:Wk 1
SA320520S_21_0066_57B6 | treatment:6E | week:Wk 4
SA320521S_21_0066_51B6 | treatment:6F | week:Wk 1
SA320522S_21_0066_214B6 | treatment:6F | week:Wk 4
SA320523S_21_0066_54B6 | treatment:6W | week:Wk 1
SA320524S_21_0066_199B6 | treatment:6W | week:Wk 7
SA320525S_21_0066_32B6 | treatment:6X | week:Wk 1
SA320526S_21_0066_68B6 | treatment:6X | week:Wk 7
SA320527S_21_0066_215B6 | treatment:6Y | week:Wk 1
SA320528S_21_0066_105B6 | treatment:6Y | week:Wk 7
SA320529S_21_0066_304B6 | treatment:6Z | week:Wk 1
SA320530S_21_0066_224B6 | treatment:6Z | week:Wk 7
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 329

Collection:

Collection ID:CO003050
Collection Summary:Fecal samples were collected on different timepoints during sensitization of the mice. Samples were freeze-dried within one week after collection and stored at -80° awaiting analysis
Sample Type:Feces
Collection Method:Spontaneous defecation
Collection Frequency:1x week
Storage Conditions:-80℃

Treatment:

Treatment ID:TR003066
Treatment Summary:Two different mice strains and two different protocols were tested: BALB/c (BC) mice and C57Bl/6 (B6) mice. The first sensitization protocol was based on Adel-Patient et al., in which 4-week-old mice received oral gavages containing ß-lactoglobulin (BLG) and cholera toxin (CT) once a week for 6 weeks 20 (treatment W), the control groups received either BLG in PBS (X), CT in PBS (Y) or PBS alone (Z). The second protocol was adapted from Shindo et al. and included intragastrical administration of BLG in PBS or oil emulsion, followed by intraperitoneal injection of sodium salicylate (SA). The latter protocol was performed 5x a week for 3 weeks. Group A received BLG in PBS + SA, group B BLG in oil + SA, group C BLG in PBS + PBS, group D BLG in oil + PBS, group E and F were vehicle controls with group E receiving PBS + SA, and group F oil + SA
Treatment Compound:Beta-lactoglobulin, cholera toxin
Treatment Route:oral gavage, intraperitoneal injection
Treatment Dose:1 mg ß-lactoglobulin (BLG) per g body weight mixed with 10 µg of cholera toxin (CT) in 0.1 mL PBS, or 1 mg BLG in 0.1 mL individual antigen solution (vehicle), which was either PBS or an oil emulsion (saline, linoleic acid, and lecithin at 5:4:1 by volume). Intraperitoneal administration of 0.1 mL PBS or PBS containing 0.2 mg sodium salicylate (SA)
Treatment Doseduration:3 or 7 weeks
Treatment Vehicle:PBS or oil emulsion
Animal Anesthesia:CO
Animal Fasting:Evening before antigen challenge
Animal Endp Euthanasia:cervical dislocation
Animal Endp Clinical Signs:severe anaphylaxis

Sample Preparation:

Sampleprep ID:SP003063
Sampleprep Summary:To extract the polar fecal metabolome, 200 mg of lyophilized homogenized feces was dissolved in 4 mL of ultrapure water, after the addition of 100 mL ISTD mixture (25 ng mL&1 of Dvaline- d8 and L-alanine-d3). Subsequent to 30 s of thorough vortexing, 1 mL of an ice-cold methanol and ultrapure water (80:20, v/ v) mixture was added. The supernatant of the solid-liquid extraction was collected after 1 min of vortexing and 10 min of rotation, followed by a 10-min centrifugation step (13 300 x g, at 4 %C). Next, the extract was passed over a polyamide filter (diameter of 25mm and pore size of 0.45 mm) (Machery-Nagel, Düren, Germany), diluted (1:3) with ultrapure water and transferred to a glass HPLCvial.
Processing Storage Conditions:-80℃
Sample Spiking:Internal standard

Combined analysis:

Analysis ID AN004829
Analysis type MS
Chromatography type Reversed phase
Chromatography system Thermo Dionex Ultimate 3000
Column Waters ACQUITY UPLC HSS T3 (150 x 2.1mm,1.8um)
MS Type ESI
MS instrument type Orbitrap
MS instrument name Thermo Q Exactive Orbitrap
Ion Mode UNSPECIFIED
Units a.u.

Chromatography:

Chromatography ID:CH003649
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Waters ACQUITY UPLC HSS T3 (150 x 2.1mm,1.8um)
Column Temperature:45
Flow Gradient:A gradient profile with following proportions (v/v) of solvent A was applied: 0e1.5 min at 98%, 1.5e7.0 min from 98% to 75%, 7.0e8.0 min from 75% to 40%, 8.0e12.0 min from 40% to 5%, 12.0e14.0 min at 5%, 14.0e14.1 min from 5 to 98%, followed by 4.0 min of re-equilibration.
Flow Rate:0.4 mL/min
Internal Standard:L-alanine-d3, D-valine-d8
Sample Injection:10 uL
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS004575
Analysis ID:AN004829
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:MS acquisition: Xcalibur Targeted data processing: Xcalibur Untargeted data acquisition: Compound Discoverer, R studio
Ion Mode:UNSPECIFIED
  logo